Shares in Elekta show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed. Investors have an opportunity to buy the stock and target the SEK 155.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at SEK 123.4 SEK in weekly data.
The company is in a robust financial situation considering its net cash and margin position.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The stock is in a well-established, long-term rising trend above the technical support level at 123.4 SEK
The company's earnings releases usually do not meet expectations.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.74 times its estimated earnings per share for the ongoing year.
The company is not the most generous with respect to shareholders' compensation.
Subsector Advanced Medical Equipment & Technology - NEC
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.